{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "44f8893a91231621c6f4bd5d9764cfdf",
    "title": "EVERCORE ISI",
    "source_uri": "2025-08-29/Updates from ODYSSEY publications pre-ESC presentationsUpdates from ODYSSEY publications pre-ESC presentations_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:15:28.185074",
      "extracted_at": "2025-10-27T00:15:28.185085"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 24,
        "successful_pages": 24,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 1,
          "reduction_ratio": 0.07893811533052042
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "7597b80328e1d4a2",
      "text": "Outperform | Target Price/Base Case: \\(\\) 60.00\\$ Company Update",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3512c5db33706dcf",
      "text": "Health Care | Biotechnology / SMID Cap",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a0fdf1ece6249f9e",
      "text": "As we look forward to the formal MAPLE & ODYSSEY presentations tmrw @ ESC, there were add! ODYSSEY publications over the last couple days. This incls various sub analyses on the final Camzyos nHCM data with helpful detail buried in the supplements/protocol. The bottom line is that there appear to be some good reasons why ODYSSEY failed that may not apply to CYTK's ACACIA (topline in 1H26). We doubt this will convince a currently skeptical investor community, but the more afi can distance itself from mava the better. We put a quick deck together ( \\(",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "89eab12dccd2c709",
      "text": "Exploratory Insights From the ODYSSEY- HCM Trial",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5ffb5e525232b5d0",
      "text": "Dual publications of sub analysis of BMY's ODYSSEY in nHCM.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "0c9d013a52243f72",
      "text": "Milind Y. Desai, MD, MBA, Yuichiro Okushi, MD, Shada Jadam, MD, Iacopo Olivotto, MD, Anjali Owens, MD, Steven E. Nissen, MD, Zoran B. Popovic, MD, PhD, Pablo Garcia- Pavia, MD, PhD, Renato D. Lopes, MD, PhD, Perry M. Elliott, MD, Fabio Fernandes, MD, PhD, Jeffrey B. Geske, MD, Lars Maier, MD, Kathy Wolski, MPH, Qiuqing Wang, MS, Wael Jaber, MD, Zhiqun Gong, MS, Viqria Flea, MD, Matthew Fronheiser, MD, Arlene Leva, MD, Ron Aronson, MD, Theodore Abraham, MD, thODYSSEY- HCM Investigators",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c8e40e64bc47881a",
      "text": "Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "05183522f7183fcf",
      "text": "Insights From the ODYSSEY- HCM Trial",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "760b26a6f0a29b8e",
      "text": "Milind Y. Desai, MD, MBA, Iacopo Olivotto, MD, Theodore Abraham, MD, Steven E. Nissen, MD, Pablo Garcia- Pavia, MD, PhD, Renato D. Lopes, MD, PhD, Perry M. Elliott, MD, Fabio Fernandes, MD, PhD, Edileide de Barros Correia, MD, Roberto Barriales- Villa, MD, PhD, Esther Zorio, PhD, Michael Arad, MD, Sung- Hee Shin, MD, Nicolas Verheyen, MD, Benjamin Meder, MD, Olga Azevedo, MD, PhD, Hiroaki Kitaoka, MD, Kathy Wolski, MPH, Qiuqing Wang, MS, Bharat Suryawanshi, MS, Zhaoqing Wang, MS, Victoria Florea, MD, Ron Aronson, MD, Anjali T. Owens, MD, the ODYSSEY- HCM Investigators",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "40434c81817d4cc1",
      "text": "Waterfall for primary endpoint results (pVO2 & KCCQ). Active vs pbo look very similar but no obvious detriment by mava vs pbo. (worst case scenario)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "40054565d1b04a7f",
      "text": "Look out for ODYSSEY's & MAPLE's presentation @ ESC",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "372b720fa0c37d98",
      "text": "Importantly, mava's rate of \\(21.5\\%\\) LVEF reduction \\( 50% throughout the study (n = 212) demonstrated an improvement in LV- global longitudinal strain at week 48 (- 0.4% [95% CI: - 0.8% to - 0.05%]; P",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b5dc7cd1f85e4e52",
      "text": "We see a large shift down in LVEF by Week 48 for a significant portion of ptns in ODYSSEY.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "7aea33703f5ac19f",
      "text": "Serial changes in LVEF demonstrate reductions of \\(",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b9486ef9f4de4703",
      "text": "For comparison, here are the results from REDWOOD- HCM Cohort 4. A much tighter LVEF spread enabled by afi's drug profile.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d0db6628ad8ca0d8",
      "text": "Fig. 3. Effect of aficamten on LVEF. LVEF measured by A, serial echocardiograms and B, in relationship to aficamten plasma concentration. Data are presented as mean and SD. Horizontal dotted lines represent the thresholds at which IP was down-titrated to the previous dosage (yellow) or was discontinued (red). \\(C_{\\text{max}}\\) maximum plasma concentration; aficamten, LVEF, left ventricular ejection fraction; SD, standard deviation.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "680fae2d1f64571c",
      "text": "Table 5.2-1: Dose Titration",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "1ba2fc6f89f85a97",
      "text": "Study TimeMeasuresChangeaVisit 3 (Week 5)bVisit 20 (Week 53)bLVEF ≥ 60%Maintain the same doseLVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%Reduce dose to the next lower dose level• 5 mg to 2.5 mgLVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%Visit 5 (Week 9)bVisit 22 (Week 57)bLVEF ≥ 60%Maintain the same doseLVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%Reduce dose to the next lower dose level• 5 mg to 2.5 mgLVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%• 2.5 mg to 1 mgVisit 7 (Week 12)Visit 25 (Week 64)LVEF ≥ 50% to &amp;lt; 65%Maintain the same doseLVEF ≥ 65%Increase dose• 1 mg to 2.5 mg• 2.5 mg to 5 mg• 5 mg to 10 mgVisit 11 (Week 24)Visit 28 (Week 72)LVEF ≥ 50% to &amp;lt; 65%Maintain the same doseLVEF ≥ 65%Increase dose• 1 mg to 2.5 mg• 2.5 mg to 5 mg• 5 mg to 10 mgVisit 15 (Week 36)Visit 32 (Week 84)LVEF ≥ 50% to &amp;lt; 65%Maintain the same doseLVEF ≥ 65%Increase dose• 1 mg to 2.5 mg• 2.5 mg to 5 mg• 5 mg to 10 mgAt any timec• If LVEF ≤ 30%, the site sonographer should notify the investigator and study intervention should be stopped immediately and permanently. This is the only situation in which the investigator is unmasked to LVEF.• If LVEF &amp;lt; 50%, site should instruct this to the participant to interrupt study intervention for at least 4 weeks after which an echo should be performed. If LVEF remains &amp;gt; 50% after at least 4 weeks, then study intervention can be resumed at the next lower dose. Do not resume study intervention until the LVEF increases to ≥ 50%. After resuming study intervention, the dose cannot be increased for at least 4 weeks. These visits can be scheduled or unscheduled.– For participants on the 1-mg dose (or corresponding placebo), resume study intervention at the same dose.– If study intervention is interrupted due to a decrease in LVEF &amp;lt; 50% on a 1-mg dose (or corresponding placebo), then study intervention should be permanently discontinued.• Study intervention should be interrupted if the maximum visit window for a dosing visit has passed and a core laboratory LVEF has not been entered into IRT. Resume study intervention when the LVEF is entered into IRT to guide dosing.During Part C, participants should return for a visit for a resting TTE to confirm safety at least 4 weeks after visits at which changes in dose could occur. This visit can be a scheduled or unscheduled visit.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "b5e9524acf3b7268",
      "text": "Abbreviations: Echo, echocardiogram, LVEF, left ventricular ejection fraction, TTE, transthoracic echocardiogram. a Dose adjustments will be made based on values of LVEF obtained at the prior schedule or unscheduled visit for echo. b Maintain the same dose when Week 5, Week 9, Week 53, or Week 57 LVEF is 55% to 59% in participants with baseline LVEF \\(\\geq 60\\%\\) and \\(",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "3d2256fcf143e93b",
      "text": "Importantly, ACACIA's titration schedule for temporary discontinuations is at LVEF \\(Dose 1 (Starting Dose) (Day 1)Dose 2a (Week 2)Dose 3a (Week 4)Dose 4a (Week 6)LVEF ≥60% on echocardiogram5 mgNext higher dose, 10 mg maxNext higher dose, 15 mg maxNext higher dose, 20 mg max",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "0be03d26d112b92b",
      "text": "After a dose is down-titrated, no further uptitration is permitted. If LVEF \\(LVEFAficament≥60%Increase dose (Weeks 2, 4, and 6 only)≥50% to &amp;lt;60%Remain on the same dose&amp;lt;50%Reduce dose (any visit)&amp;lt;40%Temporary discontinuation (any visit)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f5eb841eff98e7c4",
      "text": "- Primary and secondary endpoints will be assessed at Week 36 (Figure 2).- After Week 36 (Part 1), participants can continue in the same arm until Week 72 (Part 2) until the last randomized patient has completed follow-up at Week 36; after that, participants can roll over into a long-term OLE study.- When participants exit the study, they will have an end of treatment visit followed by a 4-week washout period, after which they will have a repeat echocardiogram, clinical examination, and blood work (end of study).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "cbb5682f7a481ed5",
      "text": "Mavacamten saw a \\(58\\%\\) NT- ProBNP reduction without a pVO2 or KCCQ benefit. Expect this to be a common talking point @ ESC.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7daf1ffca135668e",
      "text": "BACKGROUND No therapy is approved for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY- HCM (A Study of Mavacamten in Non- Obstructive Hypertrophic Cardiomyopathy [ODYSSEY- HCM]; NCT05582395) trial, the largest to date in patients with hypertrophic cardiomyopathy (HCM), evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient- reported health status).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f75a96a7da587a5c",
      "text": "OBJECTIVES The current exploratory analysis from the ODYSSEY- HCM trial reports the associations between: 1) baseline biomarkers (N- terminal pro- B- type natriuretic peptide [NT- proBNP] and high- sensitivity cardiac troponin I [cTnI]) with clinical, exercise, and echocardiographic characteristics; and 2) comparing changes in these biomarkers from baseline to week 48 between mavacamten and placebo groups.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "2d8c7acee7835599",
      "text": "METHODS Symptomatic nHCM patients were randomized to placebo or mavacamten (starting at 5 mg/d, with titration ranging from 1 to 15 mg, based on left ventricular [LV] ejection fraction). Along with clinical and echocardiographic parameters, NT- proBNP and hs- cTnI were measured for changes from baseline to week 48.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "0669facacfc80e40",
      "text": "RESULTS Among 580 randomized patients (mean age 56 ± 15 years, 266 [45.9%] women), baseline biomarkers were elevated with median NT- proBNP 917.5 ng/L (IQR: 463- 1,725 ng/L) and hs- cTnI of 29.1 ng/L (IQR: 14.4- 91.7 ng/L). On multivariable analysis, female sex, body mass index, NYHA functional class, maximal LV wall thickness, left atrial volume index, and E/e' were associated with higher baseline NT- proBNP. Only younger age and LV mass index were associated with higher baseline hs- cTnI level. At week 48, the mavacamten group had a 58% reduction in NT- proBNP (geometric mean ratio: 0.42; 95% CI: 0.37- 0.47; \\(P",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "4fe47a6eca9d40f6",
      "text": "On X- trial comparison, this effect is comparable to the \\(56\\%\\) NT- proBNP reduction from baseline seen in afacitment's REDWOOD- HCM Cohort 4 data at Week 10.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "ff3218e44ed395aa",
      "text": "Fig. 2. Proportional change from baseline in cardiac biomarkers. Data are presented as mean proportional change and \\(95\\%\\) CI. CI, confidence intervals; hs-cTnI, high-sensitivity cardiac troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "82677a80463093dc",
      "text": "The sample size calculation is based on the following assumptions informed by the MAVERICK- 006 study:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "fd874fc9b93331e8",
      "text": "Treatment effect is assumed to be an increase of 5 points in mean KCCQ- 23 CSS change from baseline to Week 48 between mavacamten and placebo (between- group effect). Common standard deviation of 14 is assumed for the change from baseline in KCCQ- 23 CSS for each treatment group. Treatment effect is assumed to be an increase of \\(1.3 \\mathrm{mL / kg / min}\\) in mean pVO2 change from baseline to Week 48 between mavacamten and placebo. Common standard deviation of 3.1 is assumed for the change from baseline in pVO2 for each treatment group.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "2258ded605695bfd",
      "text": "Table 10.2-1: Power Calculation",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "0814a56bde0dde7e",
      "text": "Alpha (2-sided)H10H20H10 or H200.0595.5%99.0%Overall = 0.05 (minimum power with graphical approach to adjust multiplicity)94.5%98.4%99.7%",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "2d3ba19fd754864c",
      "text": "Protocol Amendment No.: 03  Date: 25- Jul- 2024",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "bf5a0a3020366ef9",
      "text": "Questions have come up on how many mid- cavitary LV obstruction ptns ODYSSEY allowed on trial. Answer: \\(\\mathbf{N} = 22\\) . We did not identify a meaningful efficacy difference vs non- mid- cavitary LVO.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "649f53b3499faa30",
      "text": "Supplemental Table 3: Change from baseline in key clinical parameters at Week 48 on patients with and without midcavitary left ventricular obstruction.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "0b4389d5115d79d5",
      "text": "ParametersMavacamten group (N=289)Placebo group (N=291)Subgroup with midcavitary gradients between &amp;gt;30 to &amp;lt; 50 mm HgChange from baseline at Week 48No (N=267)Yes (N=22)p-valueNo (N=269)Yes (N=21)p-valueLVEF-5.3 ± 6.36-5.7 ± 4.110.49-0.2 ± 4.57-0.5 ± 4.720.88Max LV wall thickness, cm-2.1 ± 3.19-2.3 ± 3.170.54-0.0 ± 2.850.1 ± 3.020.66E/e&#x27;-1.5 ± 4.24-2.6 ± 4.030.32-0.3 ± 3.19-0.3 ± 4.840.98LV-GLS0.4 ± 2.570.1 ± 2.300.520.1 ± 1.950.1 ± 1.460.89TAPSE, cm-0.0 ± 0.39-0.1 ± 0.270.330.0 ± 0.34-0.2 ± 0.280.019FAC-0.9 ± 5.15-1.0 ± 4.420.920.1 ± 5.131.5 ± 4.180.25LAVI, mL/m²-3.0 ± 9.00-4.0 ± 12.270.95-1.9 ± 8.44-4.4 ± 8.730.21LA-GLS (Reservoir)0.6 ± 5.760.2 ± 5.180.970.4 ± 4.97-1.2 ± 6.660.60LA-GLS (Conduit)1.6 ± 4.67-2.5 ± 12.580.21-0.1 ± 4.02-0.6 ± 5.380.70LA-GLS (Contractile)-0.8 ± 4.31-0.1 ± 3.420.400.5 ± 4.08-0.6 ± 4.010.26KCCQ-23 CSS15.3 ± 20.0520.8 ± 16.360.1711.7 ± 17.7417.1 ± 17.170.16Peak VO₂, ml/kg/min0.6 ± 3.070.6 ± 3.000.840.1 ± 2.82-0.4 ± 1.800.41NT-proBNP (IQR), ng/L-402.0 (-1043.0, -115.5)-275.5 (-1252.0, -84.0)0.862.5 (-177.5, 243.5)-6.5 (-125.0, 211.0)0.81hs-cTnI (IQR), ng/L-10.4 (-37.1, -3.5)-8.6 (-19.7, -5.5)0.771.4 (-2.9, 14.4)1.7 (-0.6, 4.8)0.83",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "ee8e5ccabef198f1",
      "text": "peak VO2=peak oxygen consumption, KCCQ-23 CSS=Kansas City Cardiomyopathy Questionnaire 23-point clinical summary score, NT-proBNP \\(=\\) N-terminal pro-B-type natriuretic peptide, LV-GLS=left ventricular global longitudinal strain, TAPSE=tricuspid annular plane systolic excursion, FAC=fractional area change, LAVI=left atrial volume index",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "1b83983cbb6502bb",
      "text": "DISCOORDANT SIGNALS: IMAGING AND BIOMARKERS WITHOUT CLINICAL BENEFIT",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "2b026663b22e0908",
      "text": "Both substudies revealed statistically significant reductions in key parameters, with effect sizes that could be considered meaningful:",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "679de37a3475178f",
      "text": "Decreases in left ventricular mass index (mean difference \\(- 8.7 \\mathrm{g} / \\mathrm{m}^2\\) ) and wall thickness (mean difference \\(- 2.1 \\mathrm{mm}\\) ), along with modest improvements in diastolic function and left atrial strain. Fifty- eight percent and \\(51\\%\\) median reductions in N- terminal pro- B- type natriuretic peptide and high- sensitivity cardiac troponin I, respectively.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "eba74a5c05199337",
      "text": "However, these changes did not correlate with improvements in exercise capacity or health status at 48 weeks. The absence of concordant clinical benefit raises fundamental questions:",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e0fddfc5a6e8ae02",
      "text": "- Are the observed changes insufficient in magnitude to produce symptomatic relief?- Do these surrogate markers require a longer time horizon to translate into meaningful outcomes?- Is the 48-week timeframe adequate, given that structural remodeling may precede functional improvement?- Or, is it that these biologically measurable changes are not therapeutically relevant and the changes should not be cause for optimism?",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "b1c13fdd5c117783",
      "text": "AssetMavacamten (Grp 1)Mavacamten (Grp 2)Mavacamten (pooled)AficamtenTrialMAVERICK-HCMMAVERICK-HCMMAVERICK-HCMREDWOOD-HCM Cohort 4N59 (nHCM) (40 treatment; 19 pbo)59 (nHCM) (40 treatment; 19 pbo)50 (nHCM) (40 treatment; 19 pbo)40 (nHCM)Dose / Treatment200ng/ml: N=18 starting dose 5mg; adjusted at 4-wks &amp;amp; 6-wks to 1 of 4 (2.5, 5, 10 or 15mg)500ng/ml: N=21 starting dose 5mg; adjusted at 4-wks &amp;amp; 6-wks to 1 of 4 (2.5, 5, 10 or 15mg)200ng/ml or 500ng/ml starting dose 5mg; adjusted at 4-wks &amp;amp; 6-wks to 1 of 4 (2.5, 5, 10 or 15mg)10-wk treatment starting dose 5mg; adjusted at 2 weeks in 5mg intervals to max 15mg QDNYHAClass II: 0% Class III: 79% Class III: 21% b-blocker: 63% Ca-blocker 26% None: 16%Class I: 0% Class II: 86% Class III: 14% b-blocker: 62% Ca-blocker 24% None: 14%Class I: 0% Class II: 82% Class III: 18% b-blocker: 63% Ca-blocker 25% None: 15%Class I: 0% Class II: 53% Class III: 48%Background therapyLVEF: 68% NT-proBNP: 889 KCCQ-CSS: N/A SAQ7-AF: N/A e&#x27;: 8.5 (later), 5.3 (septal) E/&#x27;: 13.9 group 1: 2.3% @ wk-16LVEF: 69.4% NT-proBNP: 763 KCCQ-CSS: N/A SAQ7-AF: N/A e&#x27;: 7.7 (later), 4.5 (septal) E/&#x27;: 14.2 group 2: -5.6% @ wk-16LVEF: 69% NT-proBNP: 821 KCCQ-CSS: N/A SAQ7-AF: N/A e&#x27;: 8.1 (later), 4.9 (septal) E/&#x27;: 14.1 group 1: -2.3%; group 2: -5.6% 0.22 change from BL @ wk-16b-blocker: 73% Ca-blocker 10% LVEF: 70% NT-proBNP: 1105 KCCQ-CSS: 67.1 SAQ7-AF: 63.1 e&#x27;: 6.9 (later), 4.3 (septal) E/&#x27;: 11.6 5% @ wk-10 * 1% at wk-4 N/AResting LVEF (%)0.36 change from BL @ wk-16 53% pts w change ≥1 @ wk-160.12 change from BL @ wk-16 33% pts w change ≥1 @ wk-160.22 change from BL @ wk-16 42% pts w change ≥1 @ wk-16 No sign improvement Change: group 1 0.2 @ wk-1655% pts w change ≥1 @ wk-10 Baseline: 67; Change: 11 @ 10-wks, 8 @ 6-wks 56% ≥5 pts; 44% ≥10 pts Change: 13 pts @ wk-10, 11 @ wk-6NYHA ClassNo sign improvement Change: group 1 0.2 @ wk-16No sign improvement Change: group 2 6.2 @ wk-16No sign improvement Change:  group 1 0.2 @ wk-16 group 2 6.2 @ wk-16Change: 13 pts @ wk-10, 11 @ wk-6 56% reduction by wk-10 * 46% reduction by wk-4 *KCCQN/AN/AN/ASAQ-7-AF47% group 1 reduction by wk-16 * [45% group 1 by wk-4 *]53% group 2 reduction by wk-16 * [41% group 2 by wk-4 *]47% group 1; 53% group 2 reduction by wk-16 * [45% group 1 by wk-4 *]56% reduction by wk-10 * 46% reduction by wk-4 *NT-proBNP34% reduction by wk-16 * 20% reduction by wk-4 *34% reduction by wk-16 * 20% reduction by wk-8 *34% reduction by wk-16 * 20% reduction by wk 4 *22% reduction by wk-10 * 22% reduction by wk-4 *TroponinNo sign changesNo sign changesNo sign changesAt wk-10 lateral e&#x27;: 7 to 8 *; septal e&#x27;: 4 to 5 * E/&#x27;: 11.6 to 10.9 (lateral &amp;amp; septal) 8% pts LVEF &amp;lt;50% 1 pt fatal cardiac arrestDiastolic Biomarkers12% pts LVEF&amp;lt;45%12% pts LVEF&amp;lt;45%12% pts LVF&amp;lt;45%4 SAES not related to drug LVEF &amp;lt;40% Response Defn: &amp;gt;50% reduction in NT-proBNP &amp;gt;1 NYHA class &amp;gt;5 KCCQ-CSSSafety6 SAES (AF, systolic dysfunction, arthritis, 6 SAES (AF, systolic dysfunction, arthritis, 6 SAES (AF, systolic dysfunct, arthritis, 6 SAES (AF, systolic dysfunct, arthritis, 6 SOther Safety6 SAES (AF, systolic dysfunction, arthritis, 6 SAES (AF, systolic dysfunct, arthritis, 6 SAES (AF, systolic dysfunct, arthritis, 6 SStopping CriteriaLVEF &amp;lt;45% Composite functional endpoint: 1) pVO2 improvement of ≥1.5 ml/kg/min 1) pVO2 improvement of ≥1.5 ml/kg/min 1) pVO 2 improvement of ≥1.5 ml/kg/min 1) pVO 2 improvement of 1.5 ml/kg/min 1) pVO 2 improvement of ≥1.5 ml/kg/min 1) pVO 2 improvement of ≥1.5 mLVEF &amp;lt;45% Composite functional endpoint: 1) pVO 2 improvement of ≥1.5 ml/kg/min 1) pVO 2 improvement of ≥1.5 ml/kg/min 1) pV 2 improvement of ≥1.5 ml/kg/min 1) pVO 2 improvement of ≥1.5 ml/kg/min 1) pVO 2 improvement 1) pVO 2 improvement of ≥1.5 ml/kg/min 1) PVO 2 improvement of ≥1.5 ml/kg/min 1) pVO 2 improvement of ≥1.5 ml/kg/min 1) pVO 2 imLVEF &amp;lt;40% Response Defn: &amp;gt;50% reduction in NT-proBNP &amp;gt;1 NYHA class &amp;gt;5 KCCQ-CSSExtraw NYHA class reduction; 2) pVO 2 improvement of 3.0 ml/kg/min 2) pVO 2 improvement of 3.0 ml/kg/min 2) pV 2 improvement of 3.0 ml/kg/min 2) pVO 2 improvement of 3.0 ml/kg/min 2) pVO 2 improvement 1) pVO 2 improvement of 3.0 ml/kg/min 2) pVOw NYHA class same w NYHA class same w NYHA class same w NYHA classes same w NYHA class same w NYHA class same &amp;gt;5 KCCQ-CSS",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "1dafa3ceabb0e9a9",
      "text": "Phase 3 nHCM Trial DesignParameterAficamten (CYTK)Mavacamten (BMY)TrialACACIA-HCMODYSSEY-HCMPtn Count500580Start Date*8/30/202312/14/2022Primary Completion Date*6/1/20263/31/2025Nearest Milestone1H26 ReadoutFailLaunch Guidance2028-# of sites135225US% vs ex-US% sites41% (US) vs 59% (ex-US)18% (US) vs 82% (ex-US)Key Inclusion Criteriaresting LVOT-G &amp;lt; 30mm Hg post-Valsalva LVOT-G &amp;lt;50mg Hg LVEF ≥ 60% NYHA Class II or III pVO2 ≤ 90% based off age &amp;amp; sexresting LVOT-G &amp;lt; 30mm Hg post-Valsalva LVOT-G &amp;lt;50mg Hg NYHA Class II or IIIPrimary EndpointKCCQ &amp;amp; pVO2 @ Week 36KCCQ &amp;amp; pVO2 @ Week 48NCTNCT06081894NCT05582395",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "8a674c1261e9d7df",
      "text": "TreatmentPrimary Endpoint ResultsKey DemographicsKey Secondary EndpointsAficamtenUnderregulatoryreview(FDA &amp;amp; EMA)SEQUOIA-HCMChange in peak oxygen uptake (pVO2) by CPET from baseline to Week 24Mean Δ in pVO2 uptake:1.8mL/kg/min in aficamten arm0.0mL/kg/min in placebo armBaseline (N=282) 1:1Baseline (N=282) 1:1MetricDifference afi vs pboNYHAClass 2/3/476% vs 24% vs 0%KCCQ@ 24W+7 pts(5-10 at 95% CI)BaselineLVEF75%(Minimum 60%)NYHAimprove34%(1 class improvement)MavacamtenFDAapproved in2022EXPLORER-HCMComposite primary: 1.5 mL/kg/min or greater increase in pVO2 and at least one NYHA class reduction or a 3.0 mL/kg/min or greater pVO2 increase w/out NYHA class worsening:37% of mavacamten arm17% of placebo armBaselineLVOT*55 mmHgΔLVOT-50 mm Hg(post Valsalva at Week 24)NYHAClass 2/3/472% vs 28% vs 0%MetricDifference mava vs pboBaselineLVEF74%(Minimum 55%)KCCQ@ 24W+9.1 pts(5.5-12.7 at 95% CI)BaselineLVOT*52 mmHgΔLVOT34%(1 class improvement)-36.4 mm Hg(post Valsalva at Week 30)",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "951c00efec5c505f",
      "text": "We derive our PT using a risk adjusted DCF with a WACC of \\(10.5\\%\\) and a TGR of \\(0.5\\%\\) . The discount rate is reflective of the company's profile and the terminal growth rate reflects the company's RD engine and commercial stage.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "2e1829df99faba2a",
      "text": "Competitive risks regarding to BMY and EWTX in the NT. Regulatory risk around FDA, EMA, NMPA and ROW regulatory approval. Commercial risk competing near term against BMY. Clinical risk regarding CK- 586, omecamtiv mecarbil, and rest of pipeline.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "30604fe832bc2745",
      "text": "(Article 3(1)e and Article 7 of MAR)",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "8aa2a92b30963519",
      "text": "Time of dissemination: August 29 2025 8:55 AM ET",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "66676abb63ea5635",
      "text": "Evercore IS's recommendations are based on a stock's total forecasted return over the next 12 months. Total forecasted return is equal to the expected percentage price return plus gross dividend yield. We divide our stocks under coverage into three primary ratings categories, with the following return guidelines:",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "6f0cdbd3fc103f31",
      "text": "Outperform- the total forecasted return is expected to be greater than the expected total return of the analyst's coverage sector. In Line- the total forecasted return is expected to be in line with the expected total return of the analyst's coverage sector. Underperform- the total forecasted return is expected to be less than the expected total return of the analyst's coverage sector. Coverage Suspended- the rating and target price have been removed pursuant to Evercore ISI policy when Evercore is acting in an advisory capacity in a merger or strategic transaction involving this company and in certain other circumstances. Rating Suspended- Evercore ISI has suspended the rating and target price for this stock because there is not sufficient fundamental basis for determining, or there are legal, regulatory or policy constraints around publishing, a rating or target price. The previous rating and target price, if any, are no longer in effect for this company and should not be relied upon.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "e7634047ce0e52c6",
      "text": "Prior to October 10, 2015, the \"Coverage Suspended\" and \"Rating Suspended\" categories were included in the category \"Suspended.\"",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "35860389ad253ca7",
      "text": "FINRA requires that members who use a ratings system with terms other than \"Buy,\" \"Hold/Neutral\" and \"Sell\" to equate their own ratings to these categories. For this purpose, and in the Evercore ISI ratings distribution below, our Outperform, In Line, and Underperform ratings can be equated to Buy, Hold and Sell, respectively.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "2990f8cf45e44cc5",
      "text": "Coverage UniverseInvestment Banking Services I Past 12 MonthsRatingsCountPct.RatingsCountPct.Buy44559Buy5111Hold27036Hold145Sell132Sell00Coverage Suspended182Coverage Suspended633Rating Suspended61Rating Suspended467",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "c1f152978ccb9356",
      "text": "Issuer-Specific Disclosures 29 August 2025",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "a66f1af7f1b2ab89",
      "text": "Ratings KeyBBuyOPOutperformLLongCSCoverage SuspendedHHoldILIn LineNPNo PositionRSRating SuspendedSSellUPUnderperformSShort",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "f0fb85c197b2673d",
      "text": "This report is approved and/or distributed by Evercore Group L.L.C. (\"Evercore Group\"), a U.S. licensed broker-dealer regulated by the Financial Industry Regulatory Authority (\"FINRA\") and by International Strategy & Investment Group (UK) Limited (\"ISI UK\"), which is authorized and regulated in the United Kingdom by the Financial Conduct Authority. The institutional sales, trading and research businesses of Evercore Group and ISI UK collectively operate under the global marketing brand name Evercore ISI (\"Evercore ISI\"). Both Evercore Group and ISI UK are subsidiaries of Evercore Inc. (\"Evercore\"). The trademarks, logos and service marks shown on this report are registered trademarks of Evercore Inc.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "035cecc5ee8f11c7",
      "text": "This report is provided for informational purposes only and subject to additional restrictions contained in this disclosure. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The information and opinions in this report were prepared by employees of affiliates of Evercore. The information herein is believed by Evercore ISI to be reliable and has been obtained from public sources believed to be reliable, but Evercore ISI makes no representation as to the accuracy or completeness of such information.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "90b7e3d8f4df6110",
      "text": "Opinions, estimates and projections in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of Evercore or its affiliates and are subject to change without notice. In addition, opinions, estimates and projections in this report may differ from or be contrary to those expressed by other business areas or groups of Evercore and its affiliates.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "7facf3ba528bba67",
      "text": "Evercore ISI has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate. Facts and views in Evercore ISI research reports and notes have not been reviewed by, and may not reflect information known to, professionals in other Evercore affiliates or business areas, including investment banking personnel. Evercore ISI salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed in this research.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "2f53d3a462a0d488",
      "text": "Our asset management affiliates and investing businesses may make investment decisions that are inconsistent with the recommen dations or views expressed in this research.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "9e47336552eb54b1",
      "text": "Evercore ISI does not provide individually tailored investment advice in research reports. The financial instruments discussed in this report are not suitable for all investors and investors must make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives. This report has been prepared without regard to the particular investment strategies or financial, tax or other personal circumstances of the recipient. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to the recipient's individual circumstances, or otherwise constitutes a personal recommendation to the recipient. None of Evercore Group or its affiliates will treat any recipient of this report as its customer by virtue of the recipient having received this report.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "0640f6f56fbe0024",
      "text": "Securities and other financial instruments discussed in this report, or recommended or offered by Evercore ISI, are not insured by the Federal Deposit Insurance Corporation and are not deposits of or other obligations of any insured depository institution. If a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the price or value of, or the income derived from the financial instrument, and such investor effectively assumes such currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments described in this report, either directly or indirectly, may rise or fall. Estimates of future performance are based on assumptions that may not be realized. Furthermore, past performance is not necessarily indicative of future performance.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "ec0316c83c0751d4",
      "text": "Please note that this report was prepared for and distributed by Evercore ISI to its institutional investor and market profes sional customers.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "d397f9a8c6910417",
      "text": "Recipients who are not institutional investor or market professional customers of Evercore ISI should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "c6f3e9d5a79d4ce5",
      "text": "Electronic research is simultaneously distributed to all clients. This report is provided to Evercore ISI clients only and may not be, in whole or in part, or in any form or manner (i) copied, forwarded, distributed, shared, or made available to third parties, including as input to, or in connection with, any artificial intelligence or machine learning model; (ii) modified or otherwise used to create derivative works; or (iv) used to train or otherwise develop a generative artificial intelligence or machine learning model, without the express written consent of Evercore ISI. Receipt and review of this research report constitutes your agreement with the aforementioned limitations in use.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "5eafb30d07bc052c",
      "text": "This report is not intended for distribution to or use by any person or entity in any locality, state, country or other juris diction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Evercore Group or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is being distributed by a financial institution or other than Evercore ISI or its affiliates, that financial institution is solely responsible for such distribution and for compliance with the laws, rules and regulations of any jurisdiction where this report is distributed. Clients of that financial institution should contact that institution to effect any transaction in the securities mentioned in this report or if such clients require further information. This report does not constitute investment advice by Evercore ISI to the clients of the distributing financial institution, and neither Evercore ISI nor its affiliates, nor their respective officers, directors or employees, accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "140c5736d14b48e4",
      "text": "Evercore is not authorized to act as a financial entity, securities intermediary, investment advisor or as any other regulated entity under Mexican law, and no actions, applications or filings have been undertaken in Mexico, whether before the National Banking and Securities Commission (Comision Nacional Bancaria y de Valores \"CNBV\") or any other authority, in order for Evercore to carry out activities or render services that would otherwise require a license, registration or any other authorization for such purposes; neither is it regulated by the CNBV or any other Mexican authority. This document, nor its content, constitutes an offer, invitation or request to purchase or subscribe for securities or other instruments or to make or cancel investments, nor may it serve as the basis for any contract, commitment or decision of any kind.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "f8a712c9c5cd2336",
      "text": "For persons in the UK: In making this report available, Evercore makes no recommendation to buy, sell or otherwise deal in any securities or investments whatsoever and you should neither rely or act upon, directly or indirectly, any of the information contained in this report in respect of any such investment activity. This report is being directed at or distributed to, (a) persons who fall within the definition of Investment Professionals (set out in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the \"Order\"); (b) persons falling within the definition of high net worth companies, unincorporated associations, etc. (set out in Article 49(2) of the Order); (c) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as \"relevant persons\"). This report must not be acted on or relied on by persons who are not relevant persons.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "e037ce66ce2182bd",
      "text": "For persons in Switzerland: The distribution of these materials to persons or entities in Switzerland is not intended to, and does not, constitute a financial service under the Swiss Financial Services Act (FinSA). In particular, the distribution of these materials does not constitute the provision of personal recommendations on transactions with financial instruments (investment advice) within the meaning of Article 3(c)(4) of FinSA.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "5cc2d3a8c4e11d1e",
      "text": "For persons in Australia: Evercore does not have an Australian Financial Services License (\"AFSL\"). This report is only to be distributed to persons who fall within the definition of \"wholesale\" investors under section 761G of the Corporations Act 2001 (Cth). This report must not be acted on or relied on by persons who are not wholesale investors. Evercore relies on the relief provided under ASIC Corporations (Foreign Financial Services Providers—Limited Connection) Instrument 2017/182 to provide this report to wholesale investors in Australia without an AFSL.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "8eb1db8dd4800b4b",
      "text": "For persons in New Zealand: This material has been prepared by Evercore Group L.L.C. for distribution in New Zealand to financial advisors and wholesale clients only and has not been prepared for use by retail clients (as those terms are defined in the Financial Markets Conduct Act 2013 (\"FMCA\")). Evercore Group L.L.C. is not, and is not required to be, registered or licensed under the FMCA, and unless otherwise stated any financial products referred to in this material are generally only available in New Zealand for issue to those satisfying the wholesale investor criteria in the FMCA.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "c80accd7a30fd454",
      "text": "Applicable current disclosures regarding the subject companies covered in this report are available at the offices of Evercore ISI: 55 East 52nd Street, New York, NY 10055, and at the following site: https://evercoreisi.mediastierling.com/disclosure.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "acdd79563eac6d76",
      "text": "In compliance with the European Securities and Markets Authority's Market Abuse Regulation, a list of all Evercore ISI recommendatios disseminated in the preceding 12 months for the subject companies herein, may be found at the following site: https://evercoreisi.mediasterling.com/disclosure.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "2d3de7e1d6eb78ef",
      "text": "© 2025. Evercore Group L.L.C. All rights reserved.",
      "page": 23,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "6bfdb485e64d207a",
      "name": "ASIC Corporations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "29d6486e79d93ce9",
      "name": "After Week",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "38efa2e9cded7911",
      "name": "American College",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c11d7d0b38b067e0",
      "name": "An Editor",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bb7ba273d14196c5",
      "name": "Anjali Owens",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "92efe32237a73bc7",
      "name": "Arlene Leva",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c948b097867d16e8",
      "name": "Australian Financial",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b8bb45f6cba785a4",
      "name": "Barros Correia",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "43621786f3b3ac87",
      "name": "Benjamin Meder",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "59fb4fa4cda270c1",
      "name": "Bharat Suryawanshi",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "919ba5797636c918",
      "name": "Biological Signals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "fe0fe46365786da9",
      "name": "Both Evercore",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e0f51e60d3bfe49f",
      "name": "CONCLUSIONS Symptomatic",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "db7d56177e46a699",
      "name": "CONCLUSIONS Treatment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "174eece1254ae3da",
      "name": "Cardiac Biomarkers",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "84873a30d7c15e40",
      "name": "Cardiology Foundation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "87ac6e96c94db2e1",
      "name": "Cardiomyopathy\n\nExploratory",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ace3debb821c7085",
      "name": "Cardiomyopathy\n\nInsights",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cf2b730dfbec5c35",
      "name": "Cardiomyopathy Questionnaire",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": "Change in NT-ProBNP from Baseline to Week 48",
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Patient"
            ]
          },
          "y": {
            "unit": "ng/L",
            "range": {
              "min": -4000,
              "max": 4000
            }
          }
        },
        "series": [
          {
            "name": "Placebo",
            "unit": "ng/L",
            "values": []
          },
          {
            "name": "Mavacamten",
            "unit": "ng/L",
            "values": []
          }
        ],
        "figure_id": "3c69f2c511368f1b",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "combo",
        "title": null,
        "page": 8,
        "axes": {
          "x": {
            "type": "category",
            "labels": {
              "A": [
                "0",
                "2",
                "4",
                "6",
                "10",
                "12"
              ],
              "B": [
                "0",
                "100",
                "200",
                "300",
                "400",
                "500",
                "600",
                "700",
                "800",
                "900",
                "1000",
                "1100",
                "1200"
              ]
            }
          },
          "y": {
            "unit": {
              "A": "%",
              "B": "% LVEF"
            },
            "range": {
              "A": {
                "min": 30,
                "max": 80
              },
              "B": {
                "min": -30,
                "max": 30
              }
            }
          }
        },
        "series": [
          {
            "chart": "A",
            "name": "LVEF",
            "unit": "%",
            "values": [
              {
                "x": 0,
                "y": 70
              },
              {
                "x": 2,
                "y": 69
              },
              {
                "x": 4,
                "y": 69
              },
              {
                "x": 6,
                "y": 68
              },
              {
                "x": 10,
                "y": 65
              },
              {
                "x": 12,
                "y": 68
              }
            ]
          },
          {
            "chart": "B",
            "name": "Change from Baseline in % LVEF",
            "unit": "% LVEF",
            "values": "scatter plot data points are not extractable precisely without higher resolution or raw data, but the trend line shows a slight negative slope."
          }
        ],
        "figure_id": "69851e741be5aaa4",
        "provenance": {
          "page": 8
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Patient"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -30,
              "max": 20
            }
          }
        },
        "series": [
          {
            "name": "Placebo",
            "unit": "%",
            "values": [
              15.0,
              12.0,
              10.0,
              8.0,
              7.0,
              6.0,
              5.0,
              4.0,
              3.0,
              2.0,
              1.0,
              0.0,
              -1.0,
              -2.0,
              -3.0,
              -4.0,
              -5.0,
              -6.0,
              -7.0,
              -8.0,
              -9.0,
              -10.0,
              -11.0,
              -12.0,
              -13.0,
              -14.0
            ]
          },
          {
            "name": "Mavacamten",
            "unit": "%",
            "values": [
              8.0,
              7.0,
              6.0,
              5.0,
              4.0,
              3.0,
              2.0,
              1.0,
              0.0,
              -1.0,
              -2.0,
              -3.0,
              -4.0,
              -5.0,
              -6.0,
              -7.0,
              -8.0,
              -9.0,
              -10.0,
              -11.0,
              -12.0,
              -13.0,
              -14.0,
              -15.0,
              -16.0,
              -17.0,
              -18.0,
              -19.0,
              -20.0,
              -21.0,
              -22.0,
              -23.0,
              -24.0,
              -25.0,
              -26.0,
              -27.0,
              -28.0
            ]
          }
        ],
        "figure_id": "8e46ce92bc3c94c6",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 12,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "0",
              "2",
              "4",
              "6",
              "10",
              "12"
            ],
            "title": "Week"
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0.0,
              "max": 1.5
            },
            "title": "Proportional change from Baseline"
          }
        },
        "series": [
          {
            "name": "hs-cTnI",
            "unit": null,
            "values": [
              1.0,
              0.89,
              0.8,
              0.87,
              0.78,
              1.03
            ]
          },
          {
            "name": "NT-proBNP",
            "unit": null,
            "values": [
              1.0,
              0.68,
              0.53,
              0.45,
              0.46,
              0.95
            ]
          }
        ],
        "figure_id": "d5cd30b8ca267d3a",
        "provenance": {
          "page": 12
        }
      },
      {
        "type": "line",
        "title": "Cytokinetics, Inc. Rating History as of 08/28/2025",
        "page": 22,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "08/22",
              "11/22",
              "02/23",
              "05/23",
              "08/23",
              "11/23",
              "02/24",
              "05/24",
              "08/24",
              "11/24",
              "02/25",
              "05/25",
              "08/25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 120
            }
          }
        },
        "series": [
          {
            "name": "Close Price (p)",
            "unit": null,
            "values": [
              53,
              45,
              40,
              45,
              35,
              35,
              108,
              75,
              55,
              50,
              45,
              35,
              38
            ]
          },
          {
            "name": "Target Price (p)",
            "unit": null,
            "values": [
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              null,
              65,
              65,
              60
            ]
          }
        ],
        "figure_id": "0133a392324911a8",
        "provenance": {
          "page": 22
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": null,
            "labels": []
          },
          "y": {
            "unit": null,
            "range": {
              "min": null,
              "max": null
            }
          }
        },
        "series": [],
        "figure_id": "a6d80173e0bd2d70",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": "Planned Treatment for Period 01",
        "page": 7,
        "axes": {
          "x": {
            "type": "linear",
            "labels": "Week"
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "LVEF <60%",
            "unit": "%",
            "values": [
              {
                "x": 0,
                "y": 60
              },
              {
                "x": 48,
                "y": 60
              }
            ]
          },
          {
            "name": "LVEF <50%",
            "unit": "%",
            "values": [
              {
                "x": 0,
                "y": 50
              },
              {
                "x": 48,
                "y": 50
              }
            ]
          },
          {
            "name": "MAVACAMTEN",
            "unit": "%",
            "values": []
          },
          {
            "name": "PLACEBO",
            "unit": "%",
            "values": []
          }
        ],
        "figure_id": "f91d75770a74988a",
        "provenance": {
          "page": 7
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Patient"
            ]
          },
          "y": {
            "unit": null,
            "range": null
          }
        },
        "series": [
          {
            "name": "A - Placebo (Change in Peak VO2 from Baseline to Week 48)",
            "unit": "ml/kg/min",
            "values": "Individual patient changes, ranging from approximately -8 to 8"
          },
          {
            "name": "A - Mavacamten (Change in Peak VO2 from Baseline to Week 48)",
            "unit": "ml/kg/min",
            "values": "Individual patient changes, ranging from approximately -8 to 8"
          },
          {
            "name": "B - Placebo (Change in KCCQ-23 CSS Score from Baseline to Week 48)",
            "unit": null,
            "values": "Individual patient changes, ranging from approximately -70 to 70"
          },
          {
            "name": "B - Mavacamten (Change in KCCQ-23 CSS Score from Baseline to Week 48)",
            "unit": null,
            "values": "Individual patient changes, ranging from approximately -70 to 70"
          }
        ],
        "figure_id": "175429f21a3c4b35",
        "provenance": {
          "page": 4
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "d448bd973e821476",
        "value": 0.45899999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "performed at baseline and week 48. RESULTS Among 580 randomized patients (mean age 56 ± 15 years, 45.9% women), baseline measures included LVEF (65.8 ± 4%), maximal LV wall thickness (20.8 ± 4 mm), LV",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5a83b0ef79d4dfe6",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "randomized patients (mean age 56 ± 15 years, 45.9% women), baseline measures included LVEF (65.8 ± 4%), maximal LV wall thickness (20.8 ± 4 mm), LV mass index (122.3 ± 31 g/m²), average E/e' (13.3 ± 6",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "0c4b26b2cc3c77ac",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mass index (122.3 ± 31 g/m²), average E/e' (13.3 ± 6), and LV- global longitudinal strain (- 13.2 ± 4%). LA parameters included volume index (43.5 ± 16 mL/m²), reservoir strain (19.1 ± 9%), and condui",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b713ac9a7850337a",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rain (- 13.2 ± 4%). LA parameters included volume index (43.5 ± 16 mL/m²), reservoir strain (19.1 ± 9%), and conduit strain (- 11.6 ± 6%). At week 48, there was significant placebo- corrected treatmen",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e9c8961988755ac0",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "included volume index (43.5 ± 16 mL/m²), reservoir strain (19.1 ± 9%), and conduit strain (- 11.6 ± 6%). At week 48, there was significant placebo- corrected treatment difference with patients on mava",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2e56237c8a13cf35",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "patients on mavacamten demonstrating significant reduction in maximal LV wall thickness (- 2.1 mm [95% CI: - 2.15 to - 1.7 mm]), LV mass index (- 3.8 g/m² [95% CI: - 7.1 to - 0.5 g/m²]), and E/e' (- 1",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b09bf90536fa8fab",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "on in maximal LV wall thickness (- 2.1 mm [95% CI: - 2.15 to - 1.7 mm]), LV mass index (- 3.8 g/m² [95% CI: - 7.1 to - 0.5 g/m²]), and E/e' (- 1.3 [95% CI: - 2.0 to - 0.7]), with a - 5.3% [95% CI: - 5",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "938a66c34fab16a2",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "I: - 2.15 to - 1.7 mm]), LV mass index (- 3.8 g/m² [95% CI: - 7.1 to - 0.5 g/m²]), and E/e' (- 1.3 [95% CI: - 2.0 to - 0.7]), with a - 5.3% [95% CI: - 5.9% to - 4.1%]; P < 0.01) reduction in LVEF. A r",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e93cc1bd0ed98f08",
        "value": 0.053,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "dex (- 3.8 g/m² [95% CI: - 7.1 to - 0.5 g/m²]), and E/e' (- 1.3 [95% CI: - 2.0 to - 0.7]), with a - 5.3% [95% CI: - 5.9% to - 4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF < 50% occurred in ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "16e668f4f572229b",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3.8 g/m² [95% CI: - 7.1 to - 0.5 g/m²]), and E/e' (- 1.3 [95% CI: - 2.0 to - 0.7]), with a - 5.3% [95% CI: - 5.9% to - 4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF < 50% occurred in 62 pati",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2802c2bd77d2d15f",
        "value": 0.059000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "[95% CI: - 7.1 to - 0.5 g/m²]), and E/e' (- 1.3 [95% CI: - 2.0 to - 0.7]), with a - 5.3% [95% CI: - 5.9% to - 4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF < 50% occurred in 62 patients (21.",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "04c4898224ff72f7",
        "value": 0.040999999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7.1 to - 0.5 g/m²]), and E/e' (- 1.3 [95% CI: - 2.0 to - 0.7]), with a - 5.3% [95% CI: - 5.9% to - 4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF < 50% occurred in 62 patients (21.5%) in the ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "de0040e8ae347470",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.7]), with a - 5.3% [95% CI: - 5.9% to - 4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF < 50% occurred in 62 patients (21.5%) in the mavacamten arm vs 5 (1.7%) in the placebo arm and recover",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1ca5c7a98bae4dac",
        "value": 0.215,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "- 5.9% to - 4.1%]; P < 0.01) reduction in LVEF. A reduction in LVEF < 50% occurred in 62 patients (21.5%) in the mavacamten arm vs 5 (1.7%) in the placebo arm and recovered following drug interruption",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "64e09af0db34c926",
        "value": 0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tion in LVEF. A reduction in LVEF < 50% occurred in 62 patients (21.5%) in the mavacamten arm vs 5 (1.7%) in the placebo arm and recovered following drug interruption. Patients in the mavacamten group",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "69a46e0c300c02de",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "arm and recovered following drug interruption. Patients in the mavacamten group maintaining LVEF > 50% throughout the study (n = 212) demonstrated an improvement in LV- global longitudinal strain at w",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ca8e0d8f8b21e36c",
        "value": 0.004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "out the study (n = 212) demonstrated an improvement in LV- global longitudinal strain at week 48 (- 0.4% [95% CI: - 0.8% to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "60f2979c91572ed6",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e study (n = 212) demonstrated an improvement in LV- global longitudinal strain at week 48 (- 0.4% [95% CI: - 0.8% to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% [95% C",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5fa99f4b6441ee0a",
        "value": 0.008,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "= 212) demonstrated an improvement in LV- global longitudinal strain at week 48 (- 0.4% [95% CI: - 0.8% to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% [95% CI: - 1.8% t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "9f31d9f13a34b52b",
        "value": 0.0005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "monstrated an improvement in LV- global longitudinal strain at week 48 (- 0.4% [95% CI: - 0.8% to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "50dfae744ff1e8c8",
        "value": 0.011000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8 (- 0.4% [95% CI: - 0.8% to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improve",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "344317d44d634f2c",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".4% [95% CI: - 0.8% to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improved sign",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f47b40424cf3361a",
        "value": 0.018000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "I: - 0.8% to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improved significantly ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "30638617e9f67410",
        "value": 0.004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "to - 0.05%]; P < 0.05). LA functional parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improved significantly at week 48",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ba7461f48af47eb9",
        "value": 0.013999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ". LA functional parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improved significantly at week 48 (P < 0.05), whereas L",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b154fa299c9662e7",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "unctional parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improved significantly at week 48 (P < 0.05), whereas LA volu",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "73e955828e2ac624",
        "value": 0.006,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "parameters including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improved significantly at week 48 (P < 0.05), whereas LA volume was sig",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2a7b561a44fa12be",
        "value": 0.023,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "including contractile (- 1.1% [95% CI: - 1.8% to - 0.4%]) and conduit (- 1.4% [95% CI: - 0.6% to - 2.3%]) strain also improved significantly at week 48 (P < 0.05), whereas LA volume was significantly ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "9e7c3564de6e5593",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ", whereas LA volume was significantly reduced in patients without atrial fibrillation (- 2.6 mL/m² [95% CI: - 4.7 to - 1.11 mL/m²]; P = 0.009). CONCLUSIONS Symptomatic nHCM patients treated with mavac",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "b48a164f70359abb",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "unction, modest regression in LV hypertrophy- related parameters, but 1 in 5 demonstrated an LVEF < 50%, which reversed following therapy interruption. (JACC. 2025; 2025 by the American College of Car",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f60046ac6a5f34d7",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>Changea</td></tr><tr><td rowspan=\"2\">Visit 3 (Week 5)b<br>Visit 20 (Week 53)b</td><td>LVEF ≥ 60%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7baf656f438157c0",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "isit 20 (Week 53)b</td><td>LVEF ≥ 60%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%</td><td>Reduce dose to the next lower dose level<br>• 5 mg t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "82e69de0b0e249a2",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "eek 53)b</td><td>LVEF ≥ 60%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%</td><td>Reduce dose to the next lower dose level<br>• 5 mg to 2.5 mg</",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "fd49ac262cb00ecd",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%</td><td>Reduce dose to the next lower dose level<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>L",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7abdf937d116384a",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "educe dose to the next lower dose level<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td></td></tr><tr><td rowspan=\"2\">Visit",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e952e363d4283794",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "to the next lower dose level<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td></td></tr><tr><td rowspan=\"2\">Visit 5 (Week 9)",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "2f0f0c3fc08b2968",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "vel<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td></td></tr><tr><td rowspan=\"2\">Visit 5 (Week 9)b<br>Visit 22 (Week 57)b<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7992c1d2aecb92c0",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td></td></tr><tr><td rowspan=\"2\">Visit 5 (Week 9)b<br>Visit 22 (Week 57)b</td><td>LVEF ≥ 60",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c45763532cd35c36",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "; 65%</td><td></td></tr><tr><td rowspan=\"2\">Visit 5 (Week 9)b<br>Visit 22 (Week 57)b</td><td>LVEF ≥ 60%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f2308adea4ffe373",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "isit 22 (Week 57)b</td><td>LVEF ≥ 60%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%</td><td>Reduce dose to the next lower dose level<br>• 5 mg t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "64476e415b94561b",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "eek 57)b</td><td>LVEF ≥ 60%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%</td><td>Reduce dose to the next lower dose level<br>• 5 mg to 2.5 mg</",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "fd49ac262cb00ecd",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>Maintain the same dose</td></tr><tr><td>LVEF &amp;lt; 60% and ≥ 50% of baseline LVEF is ≥ 65%</td><td>Reduce dose to the next lower dose level<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>L",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7abdf937d116384a",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "educe dose to the next lower dose level<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td>• 2.5 mg to 1 mg</td></tr><tr><td r",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e952e363d4283794",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "to the next lower dose level<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td>• 2.5 mg to 1 mg</td></tr><tr><td rowspan=\"2\">",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "2f0f0c3fc08b2968",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "vel<br>• 5 mg to 2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td>• 2.5 mg to 1 mg</td></tr><tr><td rowspan=\"2\">Visit 7 (Week 12)<br>Visi",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7992c1d2aecb92c0",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2.5 mg</td></tr><tr><td></td><td>LVEF &amp;lt; 55% and ≥ 50% of baseline LVEF is ≥ 60% and &amp;lt; 65%</td><td>• 2.5 mg to 1 mg</td></tr><tr><td rowspan=\"2\">Visit 7 (Week 12)<br>Visit 25 (Week 64)</t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "33d808f3332dad78",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2.5 mg to 1 mg</td></tr><tr><td rowspan=\"2\">Visit 7 (Week 12)<br>Visit 25 (Week 64)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "29e22dcf8124a883",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td rowspan=\"2\">Visit 7 (Week 12)<br>Visit 25 (Week 64)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<br>• 1 mg to 2.",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c10c4c79a2f3e6e1",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(Week 64)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<br>• 1 mg to 2.5 mg<br>• 2.5 mg to 5 mg<br>• 5 mg to 10 mg</td></tr><tr><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "95f3fd14c45267fb",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5 mg to 10 mg</td></tr><tr><td rowspan=\"2\">Visit 11 (Week 24)<br>Visit 28 (Week 72)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f8ffd7dac9e459b7",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td rowspan=\"2\">Visit 11 (Week 24)<br>Visit 28 (Week 72)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<br>• 1 mg to 2.",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "df8402667485585a",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(Week 72)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<br>• 1 mg to 2.5 mg<br>• 2.5 mg to 5 mg<br>• 5 mg to 10 mg</td></tr><tr><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "95f3fd14c45267fb",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5 mg to 10 mg</td></tr><tr><td rowspan=\"2\">Visit 15 (Week 36)<br>Visit 32 (Week 84)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f8ffd7dac9e459b7",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td rowspan=\"2\">Visit 15 (Week 36)<br>Visit 32 (Week 84)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<br>• 1 mg to 2.",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f42596aa14fa2f27",
        "value": 0.65,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(Week 84)</td><td>LVEF ≥ 50% to &amp;lt; 65%</td><td>Maintain the same dose</td></tr><tr><td>LVEF ≥ 65%</td><td>Increase dose<br>• 1 mg to 2.5 mg<br>• 2.5 mg to 5 mg<br>• 5 mg to 10 mg</td></tr><tr><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "189c331a1739c020",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "to 2.5 mg<br>• 2.5 mg to 5 mg<br>• 5 mg to 10 mg</td></tr><tr><td>At any timec</td><td>• If LVEF ≤ 30%, the site sonographer should notify the investigator and study intervention should be stopped imm",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "21e10c0c1de661d9",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ly. This is the only situation in which the investigator is unmasked to LVEF.<br>• If LVEF &amp;lt; 50%, site should instruct this to the participant to interrupt study intervention for at least 4 wee",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f1e4b9abe3bffc1a",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "intervention for at least 4 weeks after which an echo should be performed. If LVEF remains &amp;gt; 50% after at least 4 weeks, then study intervention can be resumed at the next lower dose. Do not re",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "46a9afefd1aadc44",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n be resumed at the next lower dose. Do not resume study intervention until the LVEF increases to ≥ 50%. After resuming study intervention, the dose cannot be increased for at least 4 weeks. These vis",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "40ed8ced28a3faa1",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tion at the same dose.<br>– If study intervention is interrupted due to a decrease in LVEF &amp;lt; 50% on a 1-mg dose (or corresponding placebo), then study intervention should be permanently discont",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c16dde11d81f3238",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "scheduled visit for echo. b Maintain the same dose when Week 5, Week 9, Week 53, or Week 57 LVEF is 55% to 59% in participants with baseline LVEF \\(\\geq 60\\%\\) and \\(< 65\\%\\) c Based on all echocardio",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "0ed9a4c59b7f2d61",
        "value": 0.59,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ed visit for echo. b Maintain the same dose when Week 5, Week 9, Week 53, or Week 57 LVEF is 55% to 59% in participants with baseline LVEF \\(\\geq 60\\%\\) and \\(< 65\\%\\) c Based on all echocardiograms o",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "d73160a62e030af7",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "se 2a <br>(Week 2)</td><td>Dose 3a <br>(Week 4)</td><td>Dose 4a <br>(Week 6)</td></tr><tr><td>LVEF ≥60% on echocardiogram</td><td>5 mg</td><td>Next higher dose, 10 mg max</td><td>Next higher dose, 15 ",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "d254c25f686fb91d",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "gram criteria for scheduled dose titration <table><tr><td>LVEF</td><td>Aficament</td></tr><tr><td>≥60%</td><td>Increase dose (Weeks 2, 4, and 6 only)</td></tr><tr><td>≥50% to &amp;lt;60%</td><td>Remai",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "5ba2d27cb55661a5",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Aficament</td></tr><tr><td>≥60%</td><td>Increase dose (Weeks 2, 4, and 6 only)</td></tr><tr><td>≥50% to &amp;lt;60%</td><td>Remain on the same dose</td></tr><tr><td>&amp;lt;50%</td><td>Reduce dose ",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "af70628686a13cc6",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>≥60%</td><td>Increase dose (Weeks 2, 4, and 6 only)</td></tr><tr><td>≥50% to &amp;lt;60%</td><td>Remain on the same dose</td></tr><tr><td>&amp;lt;50%</td><td>Reduce dose (any visit)</td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "d538429a535e02a0",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "only)</td></tr><tr><td>≥50% to &amp;lt;60%</td><td>Remain on the same dose</td></tr><tr><td>&amp;lt;50%</td><td>Reduce dose (any visit)</td></tr><tr><td>&amp;lt;40%</td><td>Temporary discontinuation (",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "94e4ece7a3a013fe",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "the same dose</td></tr><tr><td>&amp;lt;50%</td><td>Reduce dose (any visit)</td></tr><tr><td>&amp;lt;40%</td><td>Temporary discontinuation (any visit)</td></tr></table> ## Procedures - Primary and seco",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "bbe05b5bc3c007c1",
        "value": 0.45899999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nges from baseline to week 48. RESULTS Among 580 randomized patients (mean age 56 ± 15 years, 266 [45.9%] women), baseline biomarkers were elevated with median NT- proBNP 917.5 ng/L (IQR: 463- 1,725 n",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "b6b7f3fd2f75db51",
        "value": 0.58,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s index were associated with higher baseline hs- cTnI level. At week 48, the mavacamten group had a 58% reduction in NT- proBNP (geometric mean ratio: 0.42; 95% CI: 0.37- 0.47; \\(P < 0.001\\) ) and a 5",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "902936222b038d7e",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "el. At week 48, the mavacamten group had a 58% reduction in NT- proBNP (geometric mean ratio: 0.42; 95% CI: 0.37- 0.47; \\(P < 0.001\\) ) and a 51% reduction in hs- cTnI (geometric mean ratio: 0.49; 95%",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "658c39dc2054224c",
        "value": 0.51,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "58% reduction in NT- proBNP (geometric mean ratio: 0.42; 95% CI: 0.37- 0.47; \\(P < 0.001\\) ) and a 51% reduction in hs- cTnI (geometric mean ratio: 0.49; 95% CI: 0.45- 0.53; \\(P < 0.001\\) ). No signif",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "817b62f167d22a13",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2; 95% CI: 0.37- 0.47; \\(P < 0.001\\) ) and a 51% reduction in hs- cTnI (geometric mean ratio: 0.49; 95% CI: 0.45- 0.53; \\(P < 0.001\\) ). No significant change in either biomarker was seen in the place",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "20ca3c233de1fd1c",
        "value": 0.955,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "le><tr><td>Alpha (2-sided)</td><td>H10</td><td>H20</td><td>H10 or H20</td></tr><tr><td>0.05</td><td>95.5%</td><td>99.0%</td><td></td></tr><tr><td>Overall = 0.05 (minimum power with graphical approach ",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "0a16d63e50e47932",
        "value": 0.99,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ha (2-sided)</td><td>H10</td><td>H20</td><td>H10 or H20</td></tr><tr><td>0.05</td><td>95.5%</td><td>99.0%</td><td></td></tr><tr><td>Overall = 0.05 (minimum power with graphical approach to adjust mult",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "06f14548a7016d3c",
        "value": 0.945,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Overall = 0.05 (minimum power with graphical approach to adjust multiplicity)</td><td>94.5%</td><td>98.4%</td><td>99.7%</td></tr></table> Protocol Amendment No.: 03 Date: 25- Jul- 2024<｜",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "2814b1992671be41",
        "value": 0.9840000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Overall = 0.05 (minimum power with graphical approach to adjust multiplicity)</td><td>94.5%</td><td>98.4%</td><td>99.7%</td></tr></table> Protocol Amendment No.: 03 Date: 25- Jul- 2024<｜end▁of▁sentenc",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "08c79ac8bad2b274",
        "value": 0.997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(minimum power with graphical approach to adjust multiplicity)</td><td>94.5%</td><td>98.4%</td><td>99.7%</td></tr></table> Protocol Amendment No.: 03 Date: 25- Jul- 2024<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "1a1b44eafc3150cf",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "se 5mg; adjusted at 2 weeks in 5mg intervals to max 15mg QD</td></tr><tr><td>NYHA</td><td>Class II: 0% <br>Class III: 79% <br>Class III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "40af58dfb22088ea",
        "value": 0.79,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t 2 weeks in 5mg intervals to max 15mg QD</td></tr><tr><td>NYHA</td><td>Class II: 0% <br>Class III: 79% <br>Class III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>C",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "db48423cc685b305",
        "value": 0.21,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tervals to max 15mg QD</td></tr><tr><td>NYHA</td><td>Class II: 0% <br>Class III: 79% <br>Class III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Cl",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "90dde1ffe5a17b29",
        "value": 0.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "QD</td></tr><tr><td>NYHA</td><td>Class II: 0% <br>Class III: 79% <br>Class III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-b",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "7461ee785ec17380",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>NYHA</td><td>Class II: 0% <br>Class III: 79% <br>Class III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "e869f8ae8d57951b",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Class II: 0% <br>Class III: 79% <br>Class III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "375149200ad778d4",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ss III: 79% <br>Class III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "d04bf82df9de4ee2",
        "value": 0.86,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lass III: 21% <br>b-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>C",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "93253679408281d5",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-blocker: 63% <br>Ca-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Cl",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "c4a5ca9d322960f5",
        "value": 0.62,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "a-blocker 26% <br>None: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "a028e39da911a286",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "one: 16%</td><td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "764fd746af9c63b8",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Class I: 0% <br>Class II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "ccd965a846cfed7a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ass II: 86% <br>Class III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "ecd525f537df51b0",
        "value": 0.82,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lass III: 14% <br>b-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>C",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "0f9bce60619d91dc",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-blocker: 62% <br>Ca-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>Class II: 53% <br>Cl",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "1061e1c3ca3a47f4",
        "value": 0.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "a-blocker 24% <br>None: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>Class II: 53% <br>Class III: 48%</td></",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "1d07d3e055cb7e8b",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "one: 14%</td><td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>Class II: 53% <br>Class III: 48%</td></tr><tr><td>Backgrou",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "c49234ffc54d0bd9",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Class I: 0% <br>Class II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>Class II: 53% <br>Class III: 48%</td></tr><tr><td>Background therapy</td",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "6557fd5b3debef1b",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ass II: 82% <br>Class III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>Class II: 53% <br>Class III: 48%</td></tr><tr><td>Background therapy</td><td>LVEF: 68% <br>NT",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "f2bcc17476cfc14b",
        "value": 0.53,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lass III: 18% <br>b-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>Class II: 53% <br>Class III: 48%</td></tr><tr><td>Background therapy</td><td>LVEF: 68% <br>NT-proBNP: 889 <br>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "ed4b0c5606aba7bf",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-blocker: 63% <br>Ca-blocker 25% <br>None: 15%</td><td>Class I: 0% <br>Class II: 53% <br>Class III: 48%</td></tr><tr><td>Background therapy</td><td>LVEF: 68% <br>NT-proBNP: 889 <br>KCCQ-CSS: N/A <br>S",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "83a6bb818b3ba614",
        "value": 0.68,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Class I: 0% <br>Class II: 53% <br>Class III: 48%</td></tr><tr><td>Background therapy</td><td>LVEF: 68% <br>NT-proBNP: 889 <br>KCCQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: 8.5 (later), 5.3 (septal) <br",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "741566aef5f4d7e3",
        "value": 0.023,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: 8.5 (later), 5.3 (septal) <br>E/&#x27;: 13.9 <br>group 1: 2.3% @ wk-16</td><td>LVEF: 69.4% <br>NT-proBNP: 763 <br>KCCQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: ",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "3805302ff49bd173",
        "value": 0.6940000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "A <br>e&#x27;: 8.5 (later), 5.3 (septal) <br>E/&#x27;: 13.9 <br>group 1: 2.3% @ wk-16</td><td>LVEF: 69.4% <br>NT-proBNP: 763 <br>KCCQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: 7.7 (later), 4.5 (septal) <",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "c0e8b78832ede89a",
        "value": -0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: 7.7 (later), 4.5 (septal) <br>E/&#x27;: 14.2 <br>group 2: -5.6% @ wk-16</td><td>LVEF: 69% <br>NT-proBNP: 821 <br>KCCQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: 8",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "65dcaef4e3e7591c",
        "value": 0.69,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<br>e&#x27;: 7.7 (later), 4.5 (septal) <br>E/&#x27;: 14.2 <br>group 2: -5.6% @ wk-16</td><td>LVEF: 69% <br>NT-proBNP: 821 <br>KCCQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: 8.1 (later), 4.9 (septal) <br>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "632c1de41995c031",
        "value": -0.023,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CQ-CSS: N/A <br>SAQ7-AF: N/A <br>e&#x27;: 8.1 (later), 4.9 (septal) <br>E/&#x27;: 14.1 <br>group 1: -2.3%; group 2: -5.6% <br>0.22 change from BL @ wk-16</td><td>b-blocker: 73% <br>Ca-blocker 10% <br>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "03a027d113977e90",
        "value": -0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "SAQ7-AF: N/A <br>e&#x27;: 8.1 (later), 4.9 (septal) <br>E/&#x27;: 14.1 <br>group 1: -2.3%; group 2: -5.6% <br>0.22 change from BL @ wk-16</td><td>b-blocker: 73% <br>Ca-blocker 10% <br>LVEF: 70% <br>NT",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "030a2763d5cfdd22",
        "value": 0.73,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/&#x27;: 14.1 <br>group 1: -2.3%; group 2: -5.6% <br>0.22 change from BL @ wk-16</td><td>b-blocker: 73% <br>Ca-blocker 10% <br>LVEF: 70% <br>NT-proBNP: 1105 <br>KCCQ-CSS: 67.1 <br>SAQ7-AF: 63.1 <br>e&",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "ceab8b9b4c963051",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "roup 1: -2.3%; group 2: -5.6% <br>0.22 change from BL @ wk-16</td><td>b-blocker: 73% <br>Ca-blocker 10% <br>LVEF: 70% <br>NT-proBNP: 1105 <br>KCCQ-CSS: 67.1 <br>SAQ7-AF: 63.1 <br>e&#x27;: 6.9 (later),",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "d84897fa2d5dacf7",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "group 2: -5.6% <br>0.22 change from BL @ wk-16</td><td>b-blocker: 73% <br>Ca-blocker 10% <br>LVEF: 70% <br>NT-proBNP: 1105 <br>KCCQ-CSS: 67.1 <br>SAQ7-AF: 63.1 <br>e&#x27;: 6.9 (later), 4.3 (septal) <",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "05346b07cac7b91b",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<br>KCCQ-CSS: 67.1 <br>SAQ7-AF: 63.1 <br>e&#x27;: 6.9 (later), 4.3 (septal) <br>E/&#x27;: 11.6 <br>5% @ wk-10 * <br>1% at wk-4 <br>N/A</td></tr><tr><td>Resting LVEF (%)</td><td>0.36 change from BL @ w",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "49e21fc1830a86a0",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".1 <br>SAQ7-AF: 63.1 <br>e&#x27;: 6.9 (later), 4.3 (septal) <br>E/&#x27;: 11.6 <br>5% @ wk-10 * <br>1% at wk-4 <br>N/A</td></tr><tr><td>Resting LVEF (%)</td><td>0.36 change from BL @ wk-16 <br>53% pts",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "0973b749a74f1ba2",
        "value": 0.53,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "* <br>1% at wk-4 <br>N/A</td></tr><tr><td>Resting LVEF (%)</td><td>0.36 change from BL @ wk-16 <br>53% pts w change ≥1 @ wk-16</td><td>0.12 change from BL @ wk-16 <br>33% pts w change ≥1 @ wk-16</td><",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "574fc99c4f0e13f3",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.36 change from BL @ wk-16 <br>53% pts w change ≥1 @ wk-16</td><td>0.12 change from BL @ wk-16 <br>33% pts w change ≥1 @ wk-16</td><td>0.22 change from BL @ wk-16 <br>42% pts w change ≥1 @ wk-16 <br>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "b5f5d48a3d3edf05",
        "value": 0.42,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.12 change from BL @ wk-16 <br>33% pts w change ≥1 @ wk-16</td><td>0.22 change from BL @ wk-16 <br>42% pts w change ≥1 @ wk-16 <br>No sign improvement <br>Change: <br>group 1 0.2 @ wk-16</td><td>55% ",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "cc6358b4f72fe775",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<br>42% pts w change ≥1 @ wk-16 <br>No sign improvement <br>Change: <br>group 1 0.2 @ wk-16</td><td>55% pts w change ≥1 @ wk-10 <br>Baseline: 67; <br>Change: 11 @ 10-wks, 8 @ 6-wks <br>56% ≥5 pts; 44%",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "06207e1b4fcb497c",
        "value": 0.56,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "wk-16</td><td>55% pts w change ≥1 @ wk-10 <br>Baseline: 67; <br>Change: 11 @ 10-wks, 8 @ 6-wks <br>56% ≥5 pts; 44% ≥10 pts <br>Change: 13 pts @ wk-10, 11 @ wk-6</td></tr><tr><td>NYHA Class</td><td>No ",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "b1f84fa68703f5aa",
        "value": 0.44,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>55% pts w change ≥1 @ wk-10 <br>Baseline: 67; <br>Change: 11 @ 10-wks, 8 @ 6-wks <br>56% ≥5 pts; 44% ≥10 pts <br>Change: 13 pts @ wk-10, 11 @ wk-6</td></tr><tr><td>NYHA Class</td><td>No sign improv",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "a881147cd28b4f95",
        "value": 0.56,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nge: <br> group 1 0.2 @ wk-16 <br>group 2 6.2 @ wk-16</td><td>Change: 13 pts @ wk-10, 11 @ wk-6 <br>56% reduction by wk-10 * <br>46% reduction by wk-4 *</td></tr><tr><td>KCCQ</td><td>N/A</td><td>N/A</",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "f7ed9c68ca014e55",
        "value": 0.46,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<br>group 2 6.2 @ wk-16</td><td>Change: 13 pts @ wk-10, 11 @ wk-6 <br>56% reduction by wk-10 * <br>46% reduction by wk-4 *</td></tr><tr><td>KCCQ</td><td>N/A</td><td>N/A</td><td>N/A</td><td></td></tr><",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "8ec5b103ecbec918",
        "value": 0.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>KCCQ</td><td>N/A</td><td>N/A</td><td>N/A</td><td></td></tr><tr><td>SAQ-7-AF</td><td>47% group 1 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>53% group 2 reduction by wk-16 ",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "54ff8cdff271616d",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>N/A</td><td>N/A</td><td></td></tr><tr><td>SAQ-7-AF</td><td>47% group 1 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>53% group 2 reduction by wk-16 * <br>[41% group 2 by wk-4 *]</td><td>",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "de8321d5cbcd14f5",
        "value": 0.53,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>SAQ-7-AF</td><td>47% group 1 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>53% group 2 reduction by wk-16 * <br>[41% group 2 by wk-4 *]</td><td>47% group 1; 53% group 2 reduct",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "f1a5a66d5425f1e6",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "up 1 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>53% group 2 reduction by wk-16 * <br>[41% group 2 by wk-4 *]</td><td>47% group 1; 53% group 2 reduction by wk-16 * <br>[45% group 1 by wk-",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "ebf7e83adbe86b6f",
        "value": 0.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "45% group 1 by wk-4 *]</td><td>53% group 2 reduction by wk-16 * <br>[41% group 2 by wk-4 *]</td><td>47% group 1; 53% group 2 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>56% reduction by w",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "26e9b0abc5402f25",
        "value": 0.53,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y wk-4 *]</td><td>53% group 2 reduction by wk-16 * <br>[41% group 2 by wk-4 *]</td><td>47% group 1; 53% group 2 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>56% reduction by wk-10 * <br>46",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "026ca8772ad5f411",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n by wk-16 * <br>[41% group 2 by wk-4 *]</td><td>47% group 1; 53% group 2 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>56% reduction by wk-10 * <br>46% reduction by wk-4 *</td></tr><tr><td",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "4a0f80b92a35ca54",
        "value": 0.56,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "y wk-4 *]</td><td>47% group 1; 53% group 2 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>56% reduction by wk-10 * <br>46% reduction by wk-4 *</td></tr><tr><td>NT-proBNP</td><td>34% reductio",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "3956c868f43bf938",
        "value": 0.46,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "; 53% group 2 reduction by wk-16 * <br>[45% group 1 by wk-4 *]</td><td>56% reduction by wk-10 * <br>46% reduction by wk-4 *</td></tr><tr><td>NT-proBNP</td><td>34% reduction by wk-16 * <br>20% reductio",
        "provenance": {
          "page": 15
        }
      },
      {
        "num_id": "af4970d2fb4e4893",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-</td></tr><tr><td># of sites</td><td>135</td><td>225</td></tr><tr><td>US% vs ex-US% sites</td><td>41% (US) vs 59% (ex-US)</td><td>18% (US) vs 82% (ex-US)</td></tr><tr><td>Key Inclusion Criteria</td>",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "d9fbec4cf8c36c68",
        "value": 0.59,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td># of sites</td><td>135</td><td>225</td></tr><tr><td>US% vs ex-US% sites</td><td>41% (US) vs 59% (ex-US)</td><td>18% (US) vs 82% (ex-US)</td></tr><tr><td>Key Inclusion Criteria</td><td>resting ",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "baf9c22cd5445d35",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>135</td><td>225</td></tr><tr><td>US% vs ex-US% sites</td><td>41% (US) vs 59% (ex-US)</td><td>18% (US) vs 82% (ex-US)</td></tr><tr><td>Key Inclusion Criteria</td><td>resting LVOT-G &amp;lt; 30mm",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "af3d2b284bcd3324",
        "value": 0.82,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>225</td></tr><tr><td>US% vs ex-US% sites</td><td>41% (US) vs 59% (ex-US)</td><td>18% (US) vs 82% (ex-US)</td></tr><tr><td>Key Inclusion Criteria</td><td>resting LVOT-G &amp;lt; 30mm Hg post-Val",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "5fbd72dd54dbe3e9",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lusion Criteria</td><td>resting LVOT-G &amp;lt; 30mm Hg post-Valsalva LVOT-G &amp;lt;50mg Hg LVEF ≥ 60% NYHA Class II or III pVO2 ≤ 90% based off age &amp;amp; sex</td><td>resting LVOT-G &amp;lt; 30mm",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "14c273f59f0df9ec",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "LVOT-G &amp;lt; 30mm Hg post-Valsalva LVOT-G &amp;lt;50mg Hg LVEF ≥ 60% NYHA Class II or III pVO2 ≤ 90% based off age &amp;amp; sex</td><td>resting LVOT-G &amp;lt; 30mm Hg post-Valsalva LVOT-G &amp;lt",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "a587b615b0a37848",
        "value": 0.76,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "=282) 1:1</td><td>Metric</td><td>Difference afi vs pbo</td></tr><tr><td>NYHA<br>Class 2/3/4</td><td>76% vs 24% vs 0%</td><td>KCCQ<br>@ 24W</td><td>+7 pts<br>(5-10 at 95% CI)</td></tr><tr><td>Baseline<",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "48312368e5a6ce7b",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ":1</td><td>Metric</td><td>Difference afi vs pbo</td></tr><tr><td>NYHA<br>Class 2/3/4</td><td>76% vs 24% vs 0%</td><td>KCCQ<br>@ 24W</td><td>+7 pts<br>(5-10 at 95% CI)</td></tr><tr><td>Baseline<br>LVEF",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "c4d518bf78dbe0d4",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Metric</td><td>Difference afi vs pbo</td></tr><tr><td>NYHA<br>Class 2/3/4</td><td>76% vs 24% vs 0%</td><td>KCCQ<br>@ 24W</td><td>+7 pts<br>(5-10 at 95% CI)</td></tr><tr><td>Baseline<br>LVEF</td><t",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "9121ee4163638445",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><td>NYHA<br>Class 2/3/4</td><td>76% vs 24% vs 0%</td><td>KCCQ<br>@ 24W</td><td>+7 pts<br>(5-10 at 95% CI)</td></tr><tr><td>Baseline<br>LVEF</td><td>75%<br>(Minimum 60%)</td><td>NYHA<br>improve</td><",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "243b4c3699107590",
        "value": 0.75,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>KCCQ<br>@ 24W</td><td>+7 pts<br>(5-10 at 95% CI)</td></tr><tr><td>Baseline<br>LVEF</td><td>75%<br>(Minimum 60%)</td><td>NYHA<br>improve</td><td>34%<br>(1 class improvement)</td></tr><tr><td r",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "73ee92c910d05e9a",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">@ 24W</td><td>+7 pts<br>(5-10 at 95% CI)</td></tr><tr><td>Baseline<br>LVEF</td><td>75%<br>(Minimum 60%)</td><td>NYHA<br>improve</td><td>34%<br>(1 class improvement)</td></tr><tr><td rowspan=\"3\">Mavac",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "031c63fb96a97ad2",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CI)</td></tr><tr><td>Baseline<br>LVEF</td><td>75%<br>(Minimum 60%)</td><td>NYHA<br>improve</td><td>34%<br>(1 class improvement)</td></tr><tr><td rowspan=\"3\">Mavacamten<br>FDA<br>approved in<br>2022</t",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "93ec5bfdd1262395",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "one NYHA class reduction or a 3.0 mL/kg/min or greater pVO2 increase w/out NYHA class worsening:<br>37% of mavacamten arm<br>17% of placebo arm</td><td>Baseline<br>LVOT*</td><td>55 mmHg</td><td>Δ<br>L",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "5a60eb789c459c70",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "or a 3.0 mL/kg/min or greater pVO2 increase w/out NYHA class worsening:<br>37% of mavacamten arm<br>17% of placebo arm</td><td>Baseline<br>LVOT*</td><td>55 mmHg</td><td>Δ<br>LVOT</td><td>-50 mm Hg<br>",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "4938d0f3cbcd03ab",
        "value": 0.72,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r>LVOT</td><td>-50 mm Hg<br>(post Valsalva at Week 24)</td></tr><tr><td>NYHA<br>Class 2/3/4</td><td>72% vs 28% vs 0%</td><td>Metric</td><td>Difference mava vs pbo</td></tr><tr><td>Baseline<br>LVEF</td",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "bf680aad362a0675",
        "value": 0.28,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>-50 mm Hg<br>(post Valsalva at Week 24)</td></tr><tr><td>NYHA<br>Class 2/3/4</td><td>72% vs 28% vs 0%</td><td>Metric</td><td>Difference mava vs pbo</td></tr><tr><td>Baseline<br>LVEF</td><td>74",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "2bf362604b30dba9",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">-50 mm Hg<br>(post Valsalva at Week 24)</td></tr><tr><td>NYHA<br>Class 2/3/4</td><td>72% vs 28% vs 0%</td><td>Metric</td><td>Difference mava vs pbo</td></tr><tr><td>Baseline<br>LVEF</td><td>74%<br>(M",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "5428d2e61cc9988b",
        "value": 0.74,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s 28% vs 0%</td><td>Metric</td><td>Difference mava vs pbo</td></tr><tr><td>Baseline<br>LVEF</td><td>74%<br>(Minimum 55%)</td><td>KCCQ<br>@ 24W</td><td>+9.1 pts<br>(5.5-12.7 at 95% CI)</td></tr><tr><td",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "9332c63f20a44316",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Metric</td><td>Difference mava vs pbo</td></tr><tr><td>Baseline<br>LVEF</td><td>74%<br>(Minimum 55%)</td><td>KCCQ<br>@ 24W</td><td>+9.1 pts<br>(5.5-12.7 at 95% CI)</td></tr><tr><td rowspan=\"2\"></t",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "91543a45dfb5f213",
        "value": 0.95,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "aseline<br>LVEF</td><td>74%<br>(Minimum 55%)</td><td>KCCQ<br>@ 24W</td><td>+9.1 pts<br>(5.5-12.7 at 95% CI)</td></tr><tr><td rowspan=\"2\"></td><td rowspan=\"2\"></td><td>Baseline<br>LVOT*</td><td>52 mmHg",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "12ecfb67bb7d1f3c",
        "value": 0.34,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "wspan=\"2\"></td><td rowspan=\"2\"></td><td>Baseline<br>LVOT*</td><td>52 mmHg</td><td>Δ<br>LVOT</td><td>34%<br>(1 class improvement)</td></tr><tr><td></td><td></td><td></td><td>-36.4 mm Hg<br>(post Valsal",
        "provenance": {
          "page": 17
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 8,
      "tables_count": 0,
      "numerical_data_count": 150,
      "passages_count": 76,
      "entities_count": 20
    }
  }
}